Two susceptible HLA-DRB1 alleles for multiple sclerosis differentially regulate anti-JC virus antibody serostatus along with fingolimod

Table 5 Multivariate logistic regression analysis of factors contributing to anti-JCV antibody positivity in patients with MS excluding carriers of HLA-DRB115*

Patients without HLA-DRB115* (n = 63)	OR (95% CI)	p value
HLA-DRB104*	5.50 (1.26–23.94)	0.023
Age	1.04 (0.98–1.11)	0.149
Fingolimod usage at sampling	2.40 (0.33–17.32)	0.384
Sex (male)	1.78 (0.38–8.46)	0.467
Lymphocyte count (× 1000/μL)	0.85 (0.20–3.66)	0.832

CI confidence interval, HLA human leukocyte antigen, JCV JC virus, MS multiple sclerosis, OR odds ratio

ISSN: 1742-2094